<DOC>
	<DOCNO>NCT00616161</DOCNO>
	<brief_summary>The purpose study determine minimum effective dose Istaroxime , patient require hospitalization deterioration chronic heart failure leave ventricular systolic dysfunction . This goal reach compare hemodynamic effect three different dos drug versus placebo . Efficacy measure change Pulmonary Capillary Wedge Pressure pre-infusion last assessment six hour intravenous infusion.Secondary objective evaluate safety , tolerability efficacy main hemodynamic parameter , echocardiographic echo-doppler measurement , plus preliminary pharmacokinetics drug .</brief_summary>
	<brief_title>A Phase II Trial Assess Hemodynamic Effects Istaroxime Pts With Worsening HF Reduced LV Systolic Function</brief_title>
	<detailed_description>Congestive heart failure one common cardiovascular condition presently reach epidemic proportion . The prevalence chronic heart failure rise specifically result increase longevity longer survival myocardial infarction . In 2003 , one million hospitalization primary diagnosis heart failure occur United States America , similar number report Europe , . At present , approximately 5 million Americans estimate suffer syndrome number expect continue increase increase age population . Despite advance treatment , mortality remain high U.S.A. Europe , nearly three hundred thousand patient die CHF primary contributory cause year . The total number hospital admission approach 3 million yearly HF list primary secondary diagnosis . Although patient relatively low mortality hospitalization ( le 4 % ) , readmission rate within 60 day discharge range 20 30 % mortality within 60 day discharge 5 - 10 % . The primary aim acute treatment worsen CHF alleviate symptom congestion edema , improve hemodynamic profile , preserve renal function without cause myocardial injury . Improved hemodynamics usually result relief primary symptom like dyspnea edema consequent improve sense wellbeing mental status . The improvement hemodynamics may persist pharmacological intervention use acute phase withdrawn . The need set decrease filling pressure ( RA pressure PCWP ) , increase cardiac output , without increase heart rate inducing/worsening atrial ventricular arrhythmia . In addition , agent improve diastolic function , modulate exaggerate neurohormonal response CHF preserve/protect viable non contractile myocardium ( e.g . : hibernated myocardium ) . The agent also facilitate early start life-saving therapy ( e.g . beta - blocker ) .Pre-clinical data Istaroxime show drug increase contractility without increase heart rate oxygen consumption ; furthermore improve diastolic dysfunction cause vasodilatation .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Signing write informed consent form . Male female patient age 18 85 year . Negative pregnancy test screening , woman childbearing potential . Body weight less equal 100 kg . Blood pressure SAP=150 DAP=90 mmHg . Heart rate range 60110 bpm Adequate Echo window available . Hospital admission monitor bed primary diagnosis worsen heart failure LV Ejection Fraction less equal 35 % document 2DEchocardiogram , radionuclide angiography LV angiogram within 6 month prior screen hospitalization . clinical condition patient stabilize within 48 hour hospitalization require continuous iv drug treatment need additional new oral treatment intravenous treatment administration follow 8 hour foreseen Randomisation period inclusion criterion : Any residual sign heart failure ( e.g . : Jugular Venous Distension , and/or Rales and/or Peripheral Oedema ) associate PCWP equal 20 mmHg , The last three consecutive determination PCWP , obtain stabilization period , maximum range variability 10 % . Ongoing treatment oral intravenous inotropes and/or inodilators . Patient treat digoxin within last week , randomise plasma concentration digoxin test randomisation value le 0.5 ng/ml . Intermittent inotropes administration within 2 week . Symptoms Heart Failure randomization e.g . : dyspnoea Systolic blood pressure &lt; 90 mmHg . Atrial fibrillation within 2 week . Left Ventricular Bundle Branch Block Cardiogenic shock mechanical ventilation . Creatinine level &gt; 3.0 mg/dl require dialysis treatment . Left ventricular failure primarily uncorrected obstructive valvular disease , hypertrophic obstructive cardiomyopathy , restrictive/obstructive cardiomyopathy , uncorrected thyroid disease , know acute myocarditis , know amyloid cardiomyopathy . Artificial heart valve . Electrical device implant ( ICD , CRT ) Evidence acute coronary syndrome within 3 month . History stroke transient ischemic attack 6 month prior screen . History sustain ventricular tachycardia . Coronary bypass graft PTCA within last 30 day INR &gt; 1.5 . Status post successful cardiac resuscitation . Serum K &lt; 3.5 mEq/l &gt; 5.3 mEq/l prior treatment . ALT , AST &gt; 3 time upper normal limit prior treatment . Hemoglobin &lt; 10 g/dl ( either gender ) prior treatment . Other clinically significant laboratory medical condition , opinion Investigator make patient unsuitable evaluation study . Anticipated survival le 2 month concomitant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Acute Heart Failure</keyword>
	<keyword>Inotropes</keyword>
	<keyword>Lusitropic agent</keyword>
	<keyword>Istaroxime</keyword>
	<keyword>PST2744</keyword>
</DOC>